Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 165INDUSTRY 98NIH 24NETWORK 2OTHER_GOV 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Interventional × ibrutinib × Clear all
NCT02436707 2026-04-20

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase 2 Active not recruiting
129 enrolled
Lymphoid

Lymphoma

NCT05998642 2026-04-14

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Canadian Cancer Trials Group

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡